Mirum Pharmaceuticals appointed Rob Myers, M.D., to replace Joanne Quan, M.D., as chief medical officer, while approving Quan’s 2026 annual target Bonus at the 100% achievement level. Investors must track the September Leadership handover and expected separation terms, including severance eligibility and changes to vested stock-option exercise rights.
Key Highlights
- Rob Myers is expected to begin employment on September 21, while Joanne Quan’s employment is expected to end on October 19.
- Mirum expects to provide the completed separation agreement with a later quarterly or annual report, subject to its effective date.
- Rob Myers, M.D. Is expected to become Mirum Pharmaceuticals’ chief medical officer after beginning employment on September 21.
Quan’s 2026 annual target bonus was approved at the 100% achievement level, subject to conditions in the final separation agreement. Myers is expected to start on September 21. Quan stopped serving as chief medical officer on September 2, and her employment is expected to end on October 19.
Separation Terms Include Bonus and Option Changes
Mirum (NASDAQ: MIRM) expects to enter into a separation agreement with Quan in connection with her departure. Mirum expects to include the completed agreement with its Quarterly Report covering the three months ending September 30 or its Annual Report for the year ending December 31, subject to the agreement’s effective date.
FAQs
Q: Who is becoming Mirum Pharmaceuticals’ chief medical officer?
A: Rob Myers, M.D. Is expected to become Mirum Pharmaceuticals’ chief medical officer after beginning employment on September 21. He will succeed Joanne Quan, M.D.
Q: What happens to Joanne Quan’s compensation and stock options?
A: Quan is expected to receive severance benefits under Mirum’s Severance Plan. Her 2026 annual target bonus was approved at the 100% achievement level, and her vested stock-option exercise period will be extended subject to conditions.
Q: When will Joanne Quan leave Mirum Pharmaceuticals?
A: Quan stopped serving as chief medical officer on September 2. Her employment termination is expected on October 19, with the final separation terms subject to the agreement.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.